Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2005

View Archived Issues

Promising preclinical results reported for novel p38alpha MAP kinase inhibitors

Highly selective Cdk4/6 inhibitor discovered

Cytokinetics selects cardiac myosin activator for development candidate

Diffusion and NABTT sign agreement for TSC clinical trials

CMC Biopharmaceuticals to produce BSSL for Arexis studies

STELLAR 3 results for Xyotax in NSCLC

ViroLogic and AstraZeneca plan Iressa biomarker study

New preclinical and clinical data available for rotigotine in Parkinson's disease

Studies reveal safety and treatment benefits of rasagiline in Parkinson's disease

Mechanisms of CP-690550 evoked immunosuppression

Interaction of estrogen and epidermal growth factor receptors in the etiology of lung cancer

Cytyc completes Proxima Therapeutics acquisition

IP-751 effective in animal model of interstitial cystitis

New phase III trial studies BAY 43-9006 for advanced liver cancer

ED-71 promotes bone formation and blocks bone resorption in mice

Esculetin prodrug protects against disc degeneration in rabbits

2MD shows promise as an anabolic agent for the treatment of inadequate bone formation

Telavancin exerts its antibacterial actions via multifunctional mechanisms

Enrollment open in phase Ib/IIa study of INO-1001 for glioblastoma multiforme

Labopharm seeks Mexican approval for once-daily tramadol

deCODE opens phase I study for DG-041 for atherosclerosis

Enrollment completed in phase II HIV study of TNX-355

AVE-0010 completes phase IIa study in type 2 diabetes

Yamanouchi may terminate PYM-50028 licensing agreement with Phytopharm

Novel cannabinoid receptor modulators prepared at the University of Tennessee

GSK reports the discovery of new ROCK/Aurora kinase inhibitors

Two series of glucosylceramide synthase inhibitors claimed by Oxford GlycoSciences

GSK discloses three series of Gly-T1 transporter inhibitors for schizophrenia

Two series of novel serine protease inhibitors described by Genentech scientists

FDA issues public health advisory for Elidel and Protopic